The Role of the Muscle-nervous System Interface in Cancer Cachexia
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Agrin fragment c-terminus CAF in cancer and cancer cachexia
研究概览
简要总结
Sarcopenia is an important component of cachexia associated with cancer, and their high incidence in cancer patients emphasizes the need for a better understanding of its mechanisms, which can result in better therapeutic interventions to reverse this situation and improve the prognosis. Our hypothesis is that the plasma concentration of IL-6 and c-terminal agrin is directly correlated with the loss of muscle mass and development of cachexia.
详细描述
The agrin is a protein that acts on neuromuscular junctions (NMJs) promoting stabilization of same, which results in the maintenance and growth of muscle fibers, but the cleavage of agrin, a process by which is formed the agrin fragment C-terminus (CAF), has been linked to the development of sarcopenia, because its presence is directly linked to the reduction in the number of muscle fibers, increasing the heterogeneity of fiber size, presence of Central cores and increasing the proportion of type I fibers and consequently a greater degradation of lean body mass. Studies in mice show that the greatest cleavage of agrin carries on development of sarcopenia and human studies report that individuals with higher serum levels of sarcopenia CAF compared to individuals without sarcopenia.
Therefore, aiming at the complexity of cancer associated with the cachexia and the great importance of the maintenance of lean body mass to a better prognosis in disease, is of fundamental importance to elucidate the role of CAF and the factors associated with sarcopenia, the possible use of these proteins for diagnosis and the contribution that this clarification could bring in clinical therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •cancer diagnosis
排除标准
- •continuously use of anti-inflammatory medications;
- •present renal and/or liver failure,
- •inflammatory bowel disease or chronic inflammatory processes not related to cachexia.
结局指标
主要结局
Agrin fragment c-terminus CAF in cancer and cancer cachexia
时间窗: 1 month
To measure the contents of agrin fragment c-terminus (CAF) in plasma of patient with cancer and cancer cachexia.
Agrin fragment c-terminus (CAF) and IL-6 and lean body mass
时间窗: 1 month
To correlate levels of agrin fragment c-terminus (CAF) and IL-6 with the lean body mass
Agrin fragment c-terminus CAF and IL-6 levels
时间窗: 1 month
To correlate levels of agrin fragment c-terminus (CAF) and IL-6 plasma levels in patients with cancer and with cancer cachexia.
Agrin fragment c-terminus CAF in cancer sarcopenia
时间窗: 1 month
To analyze correlation between Agrin fragment c-terminus CAF and the lean body mass (CT-scan estimated) of patients with cancer and with cancer cachexia.
次要结局
未报告次要终点
研究者
Alessandro Laviano
Alessandro Laviano, MD associate professor of Internal Medicine
University of Roma La Sapienza